Altering cancer treatment dosing could reduce climate impact, study finds

Model estimates potential to reduce greenhouse gas emissions by delivering treatment every 6 weeks

5:00 AM

Author | Nicole Fawcett

woman putting something in vial in lab coat and purple gloves, glasses and mask in clinical looking area
Credit: Erica Reist Bass, Michigan Medicine

Changing how often a popular cancer therapy is delivered would reduce greenhouse gas emissions and improve environmental impact without decreasing cancer survival, according to an analysis from researchers at the University of Michigan Health Rogel Cancer Center.

The team looked at 7,813 veterans receiving the immunotherapy treatment pembrolizumab through the Veterans Health Administration. 

Pembrolizumab is an intravenous treatment that is often given every three weeks at a standard, one-size-fits-all dose of 200 milligrams. 

Researchers estimated the environmental impact of patients coming in for this care every three weeks: carbon dioxide emissions from patients’ transportation to and from the clinic, manufacturing of the drug, and medical waste like needles, tubing and bags used during the compounding and infusing process.

Then they considered alternative scenarios. 

What if patients received 400 milligrams of pembrolizumab every six weeks, a dose approved by the United States Food and Drug Administration? 

What if they received a dose proportionate to their weight instead of the standard dose, as pembrolizumab was originally approved by FDA? 

Data suggests these approaches achieve cancer outcomes equivalent to the standard three-week flat dosing and likely reduce the burdens of cancer treatment that patients face.

They found that for this cohort of patients, extending treatments to every six weeks instead of every three weeks would have required 15,000 fewer infusions. 

That means 15,000 fewer trips to the clinic and 15,000 fewer incidences of compounding and infusing treatments. 

SEE ALSO: Changing the way immune-based cancer drugs are delivered could reduce costs by 14%

In total, this change would reduce greenhouse gas emissions in just the VHA by 200 tons per year. Results are published in The Lancet Oncology.

“As providers, every time we’re with a patient we’re faced with this litany of decisions that both we and the patient have to make. Those decisions – every three week dosing or every six week dosing – seem small but they really add up,” said study author Garth W. Strohbehn, M.D., M.Phil., assistant professor of internal medicine at Michigan Medicine.

Next, researchers looked at the impact that the reduced carbon emissions could have on climate change and human health – not just for the person with cancer, but for all of us, due to rising global temperatures. 

The model indicates that by continuing the current trends in pembrolizumab dosing instead of changing to less-frequent dosing, about three more people will die per year between now and 2100 because of the extra greenhouse gas emissions.

“There will more than likely be folks completely uninvolved in cancer care who are harmed by choosing to dose this medicine the way that we do. It doesn’t need to happen,” said Strohbehn, who is also a member of the U-M Institute for Healthcare Policy and Innovation and early career research scientist at the VA Ann Arbor Center for Clinical Management Research

“That’s the point we’re trying to make here: There are likely to be health costs that non-patients in a society can expect to bear when we choose to practice cancer care the way we do. Do we have a moral obligation to change the way we’re doing things if the patient in front of us is not harmed by it?”

Patient transportation to and from appointments was the biggest driver of carbon emissions, researchers found, which suggests that less-frequent infusion treatments would not only help the environment but also potentially improve patient quality of life due to fewer trips to the hospital. 

Researchers also estimated significant cost savings for VHA from the alternative dosing regimens since the total amount of drug used with the weight-based doses is lower than the one-size-fits-all approach, echoing earlier findings from Strohbehn’s team.

The study authors suggest that multiple policy actions would need to be aligned to facility this change. 

They suggest payers could develop targeted incentives around environmentally conscious care. Professional societies could alter guidelines with environmental sustainability in mind, where patient outcomes are not expected to be impacted by the adoption of more sustainable care.

Requiring environmental report cards for individual drugs at the time of approval could also increase awareness.

“I think there’s value in holding a mirror up to the conventional system and encouraging self-reflection,” Strohbehn said.

Additional authors: Alex K. Bryant, Jacqueline R. Lewy, R. Daniel Bressler, Zoey Chopra, Derek J. Gyori, Brian G. Bazzell, Julie A. Moeller, Sofia I. Jacobson, A. Mark Fendrick, Eve A. Kerr, Nithya Ramnath, Michael D. Green, Timothy P. Hofer, Parth Vaishnav

Listen to The Lancet Oncology’s podcast with Strohbehn.

Bryant, Ramnath, Green, Hofer and Strohbehn are supported by the National Cancer Institute grant P30 CA046592. 

Paper cited: “Projected environmental and public health benefits of extended-interval dosing: An analysis of pembrolizumab use in a U.S. national health system,” The Lancet Oncology. DOI: 10.1016/S1470-2045(24)00200-6

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week by subscribing to Health Lab’s two newsletters, Health & Wellness and Research & Innovation.

Sign up for the Health Lab Podcast: Add us on SpotifyApple Podcasts or wherever you get you listen to your favorite shows.


More Articles About: Cancer (Oncology) Cancer Research Cancer Treatment Health Care Delivery, Policy and Economics
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories two women, one older one younger, looking concerned listening to a provider across from them with back to camera
Health Lab
Many breast cancer survivors don't receive genetic testing, despite being eligible
As cancer treatment and survivorship care relies more on understanding the genetic make up of an individual’s tumor, a study from the University of Michigan Health Rogel Cancer Center finds that many breast cancer survivors who meet criteria for genetic counseling and testing are not receiving it.
gun with lock on it with key there gun is in black and background yellow and lock is white
Health Lab
New Michigan laws make storing firearms safely more important than ever
New safe gun storage laws for Michigan highlight the need for keeping firearms locked up and separate from ammunition to prevent injury and death including suicide.
a patient with a medical professional in scrubs in an exam room talking
Health Lab
Speculum exams unnecessary for HPV screening
HPV screening usually entails a speculum-based exam, which is an uncomfortable experience for most patients. University of Michigan researchers are the first to demonstrate in the United States that self-sampling is just as effective as speculum-based testing for HPV detection.
graphic drawing of hospital with road in front of it with red car driving
Health Lab
Long drives, high costs stand between rural adults and safe surgery
Rural patients face long drives for surgery, especially if they want to reach a high quality and affordable hospital.
blood test bottles above arm with white bandaid
Health Lab
How can we cut wasteful pre-surgery testing?
Pre-operative tests in low-risk surgical patients dropped sharply, and safely, after a quality improvement effort aimed at reducing inappropriate care.
two Black women standing next to eachother, one in a pink tank top, one in long sleeve purple shirt, with yoga purple matts
Health Lab
Using culture to encourage exercise can help close a cancer survival gap – and improve quality of life 
Angela Fong, Ph.D., an assistant professor of applied exercise science at the University of Michigan School of Kinesiology and a member of the University of Michigan Health Rogel Cancer Center, says a variety of factors can contribute to a lower five-year survival rate of cancer among members of racialized and historically marginalized groups.